Regencell Bioscience Holdings Ltd
RGC · XNASCIK 1829667fmd_1FP9A7Z4QSVT7T6VM4JX410AYWManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jul 01, 2018 to Jun 30, 2026, 8 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 0 | 0 | 0 | 3 | 2 | 1 | 1 | 1 |
| Selling, general and administrative | 0 | 0 | 1 | 5 | 5 | 4 | 3 | 10 |
| Total operating expenses | 0 | 1 | 1 | 8 | 6 | 5 | 4 | 12 |
| Operating income | (0) | (1) | (1) | (8) | (6) | (5) | (4) | (12) |
| Interest and investment income | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (0) | (1) | (1) | (8) | (6) | (4) | (4) | (12) |
| Net income | (0) | (1) | (1) | (7) | (6) | (4) | (4) | (12) |
| Net income to common shareholders | – | 1 | (1) | (7) | (6) | – | – | – |